Ani Pharmaceuticals (ANIP) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q4 2024 value amounting to $67.7 million.
- Ani Pharmaceuticals' Accumulated Depreciation & Amortization rose 1327.96% to $67.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $67.7 million, marking a year-over-year increase of 1327.96%. This contributed to the annual value of $67.7 million for FY2024, which is 1327.96% up from last year.
- Per Ani Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $67.7 million for Q4 2024, which was up 1327.96% from $59.8 million recorded in Q4 2023.
- Ani Pharmaceuticals' Accumulated Depreciation & Amortization's 5-year high stood at $67.7 million during Q4 2024, with a 5-year trough of $13.9 million in Q1 2020.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $23.0 million (2021), whereas its average is $29.3 million.
- As far as peak fluctuations go, Ani Pharmaceuticals' Accumulated Depreciation & Amortization plummeted by 1354.41% in 2020, and later surged by 14817.91% in 2022.
- Ani Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $17.5 million in 2020, then soared by 30.98% to $23.0 million in 2021, then soared by 148.18% to $57.0 million in 2022, then increased by 4.95% to $59.8 million in 2023, then rose by 13.28% to $67.7 million in 2024.
- Its Accumulated Depreciation & Amortization was $67.7 million in Q4 2024, compared to $59.8 million in Q4 2023 and $27.3 million in Q1 2023.